Inflarx Stock Price, News & Analysis

InflaRx (Nasdaq: IFRX) will participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA from November 10–12, 2025. The company will appear in a fireside chat on November 11 at 2:30 PM ET and will hold one-on-one investor meetings the same day. A live stream and replay link for the fireside chat will be provided.

InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics that target the complement system, developing vilobelimab (intravenous anti-C5a antibody) and INF904 (oral C5a receptor inhibitor). The company has offices in Jena and Munich, Germany, and Ann Arbor, MI.

InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company maintained a closing bid price of $1.00 or higher for 10 consecutive business days from August 27 to September 10, 2025.

InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor. Their key product is vilobelimab, an intravenous first-in-class anti-C5a monoclonal antibody, alongside INF904, an oral small molecule inhibitor. The company, founded in 2007, operates from offices in Jena and Munich, Germany, and Ann Arbor, Michigan.

InflaRx (NASDAQ:IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has announced its participation in two major investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference (September 3-5) with a fireside chat on September 4th at 9:10 AM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference (September 8-10) with a presentation on September 9th at 3:30 PM ET.

InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor. Their lead product, vilobelimab, is an intravenous anti-C5a monoclonal antibody, and they are also developing INF904, an oral small molecule C5a receptor inhibitor.

InflaRx (NASDAQ:IFRX) reported Q2 2025 financial results and provided key updates on its pipeline. The company's cash position stands at €53.7 million, with runway extending into 2027. Key developments include anticipated INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by early November 2025.

Financial highlights show a net loss of €23.0 million (€0.35 per share) for H1 2025. The company's partner Staidson BioPharmaceuticals reported favorable Phase 1/2 results for BDB-001 in ANCA-associated vasculitis, planning to advance to Phase 3. The previously announced Phase 3 pyoderma gangrenosum trial was stopped due to futility, with full data analysis expected later this year.

Additionally, enrollment began in the BARDA-funded JUST BREATHE Phase 2 platform trial investigating vilobelimab for acute respiratory distress syndrome (ARDS). The company maintains EU approval for GOHIBIC (vilobelimab) in SARS-CoV-2-induced ARDS and is pursuing commercial partnerships.

InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has scheduled its second quarter 2025 financial results announcement for August 7, 2025, before market opening. No earnings call is planned.

The company specializes in developing therapeutics targeting the complement system, particularly the C5a inflammatory mediator. Their key developments include vilobelimab, an intravenous anti-C5a monoclonal antibody, and INF904, an oral small molecule C5a receptor inhibitor. InflaRx maintains operations in Jena and Munich, Germany, and Ann Arbor, Michigan, USA.

InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has received a Nasdaq deficiency notice on July 11, 2025, for failing to maintain the minimum bid price requirement of $1.00 per share for the last 30 consecutive business days.

The company has been granted an initial 180-day period until January 7, 2026, to regain compliance. If unsuccessful, InflaRx may consider transferring from Nasdaq Global Select Market to Nasdaq Capital Market, which could provide an additional 180 days until July 6, 2026, subject to meeting other listing requirements.

InflaRx develops anti-C5a and anti-C5a receptor technologies, including vilobelimab, an intravenous antibody, and INF904, an oral small molecule inhibitor.

InflaRx (IFRX) announced that the Independent Data Monitoring Committee has recommended stopping the Phase 3 trial of vilobelimab for pyoderma gangrenosum (PG) due to futility. The decision was based on data from the first 30 patients, with no unexpected adverse events reported. In response, InflaRx will discontinue vilobelimab development for PG and redirect resources to INF904, their oral C5aR inhibitor. Phase 2a data readouts for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa are expected this summer. The company is considering additional cost savings to extend its cash runway. GOHIBIC (vilobelimab) remains available in the US under Emergency Use Authorization for COVID-19 treatment and has received EU marketing authorization under exceptional circumstances for SARS-CoV-2-induced ARDS patients.

InflaRx (IFRX) has announced its participation in three major investor conferences in June and July 2025. The company will present at the Jefferies Global Healthcare Conference on June 4th at 7:35 AM ET, participate in a dermatology panel at the Oppenheimer Innovators in I&I Summit on June 25th, and conduct one-on-one meetings at the Leerink Partners Therapeutics Forum on July 8th. InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, developing treatments targeting the complement system. Their lead product, vilobelimab, is an intravenous anti-C5a monoclonal antibody, while INF904 is their oral small molecule C5a receptor inhibitor in development.

InflaRx (IFRX) reported Q1 2025 financial results and key business updates. The company maintains a strong financial position with €65.7 million in cash and equivalents as of March 31, 2025, providing runway into 2027. Key upcoming catalysts include an interim analysis for vilobelimab's Phase 3 trial in pyoderma gangrenosum (PG) expected in May-June 2025, and topline Phase 2a data for INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025. The company recently completed successful toxicology studies for INF904 and received EU marketing authorization for GOHIBIC (vilobelimab) for SARS-CoV-2-induced ARDS. Q1 2025 resulted in a net loss of €8.3 million (€0.13 per share), improved from €9.7 million loss in Q1 2024. In February 2025, InflaRx raised €28.7 million through a public offering.